Vol 1, No 3 (2010)
Review paper
Published online: 2010-07-27
Compliance during therapy of patients with chronic myeloid leukemia
Hematologia 2010;1(3):239-243.
Abstract
Continuous and adequate BCR-ABL1 tyrosine kinase inhibitors (TKI) dosing is essential to
achieve optimal therapeutic outcomes in patients with chronic myeloid leukemia (CML). Hence,
patient adherence, defined as the extent to which a person’s behavior corresponds with the
agreed recommendations of a healthcare provider, is critical. Though often trivialized as
a patient problem, adherence behavior is influenced also by the clinician and the healthcare
system, the disease and its treatment, and economic and social factors. In this paper, the issue
of non compliance in patients with CML treated with TKI is reviewed. Possible interventions
how to improve the adherence is also discussed.
Hematologia 2010; 1, 3: 239-243
Hematologia 2010; 1, 3: 239-243
Keywords: compliancechronic myeloid leukemiatyrosine kinase inhibitors